Epoxide hydrolases (EHs) constitute a small protein family, first characterized as a group of detoxifying enzymes (Oesch et al., 1973). The first EHs were identified more than 40 years ago, and, to date, five genes encoding EH have been identified in humans (Decker et al., 2012; Fretland and Omiecinski, 2000). Human microsomal and soluble EHs (mEH and sEH), also named EPHX1 and EPHX2, respectively, are the best known EHs. Structurally, they are alpha/beta hydrolase fold enzymes. They catalyze the rapid hydrolysis of epoxides, which are three membered cyclic ethers, to less-reactive and readily excretable diols (Oesch et al., 1971). In mammals, epoxides arise from cytochrome P450 (CYP450) oxidative metabolism of both xenobiotics and endogenous compounds (El-Sherbeni and El-Kadi, 2014). Epoxides from xenobiotics are involved in the development of cancers and organ damage through interaction with DNA, lipids, and proteins (Nebert and Dalton, 2006), and EHs are necessary for their detoxification. On the other hand, epoxides derived from endogenous fatty acids, called epoxy fatty acids (EpFAs), are important regulatory lipid mediators. They were shown to mediate several biological processes, including inflammation, angiogenesis, vasodilation, and nociception. By regulating EpFAs levels, EHs play a key role in regulating crucial signaling pathways for cellular homeostasis (McReynolds et al., 2020), and altered levels of EpFAs are associated with many disorders (Morisseau and Hammock, 2013). Although a large amount of work has been made to characterize EH functions, especially through the use of specific inhibitors and animal models, the full spectrum of their substrates and associated biological functions in human remain partly unknown (Gautheron and Jéru, 2020). It is also a challenge to clearly define the contribution of each EH in human disorders.

Association studies suggested a role of several single-nucleotide polymorphisms (SNPs) identified in EPHX1 [MIM132810] and EPHX2 [MIM132811] in multiple conditions, including liver cirrhosis, alcohol dependence, Crohn’s disease, chronic obstructive pulmonary disease, preeclampsia, diabetes mellitus, and many cancers (El-Sherbeni and El-Kadi, 2014; Václavíková et al., 2015). This underscores the pleiotropic and crucial role of EHs in cell homeostasis, but no high-effect variants have been reported to date. In the present study, we identified two unrelated patients with a complex lipoatrophic and neurodevelopmental syndrome with severe metabolic manifestations and carrying a de novo variant in EPHX1 identified by whole-exome sequencing (WES). Lipoatrophic diabetes, also known as lipodystrophic syndromes, are characterized by clinical lipoatrophy due to a defect in adipose tissue storage of triglycerides. This results in ectopic lipid infiltration of non-adipose tissues leading to insulin resistance, increased liver glucose production, hypertriglyceridemia, and liver steatosis. About 30 genes have been implicated in lipoatrophic diabetes (Brown et al., 2016). Although these disorders remain genetically unexplained in the vast majority of cases, there is growing interest in identifying their molecular and cellular bases to improve genetic counseling and personalize treatment (Letourneau and Greeley, 2018; Sollier et al., 2020).

EPHX1 is widely expressed with highest expression in the liver, adipose tissue, and adrenal glands (Coller et al., 2001). It was the first mammalian EH to be identified and was first purified from rabbit liver in the 1970s. It is an evolutionarily highly conserved biotransformation enzyme retained in microsomal membranes of the endoplasmic reticulum (ER) (Coller et al., 2001). For a long time, EPHX1 and EPHX2 were thought to simply fulfill distinct complementary roles (Decker et al., 2009). On the one hand, EPHX1 was well recognized to detoxify xenobiotic epoxides. On the other hand, EPHX2 was shown to hydrolyze endogenous terpenoid epoxides and EpFAs (El-Sherbeni and El-Kadi, 2014). More recently, EPHX1 was also shown in animal models to play a significant role in the hydrolysis of different endogenous EpFAs derived from polyunsaturated fatty acids (Edin et al., 2018; Snider et al., 2007; Marowsky et al., 2017; Blum et al., 2019). These EpFAs, including epoxyeicosatrienoic acids (EETs) and epoxyoctadecenoic acids (also called EpOMEs), are formed by ER-attached CYP450s and hydrolyzed by EPHX1 to their respective diols, the so-called dihydroxyeicosatrienoic acids (DHETs) and dihydroxyoctadecenoic acids (DiHOMEs), respectively. Nevertheless, from an evolutionary perspective, EPHX1 and EPHX2 are very different enzymes, which can be differentially inhibited by distinct chemical inhibitors, and display only a partially overlapping substrate selectivity.

The EPHX1 variants identified in the studied patients are localized in the catalytic domain of the enzyme and were predicted to be pathogenic. This prompted us to assess their functional consequences in several cellular models. The impact of the loss of EPHX1 activity on adipocyte differentiation and function was evaluated by developing CRISPR-Cas9-mediated genome-editing approaches.

This translational study presents the first example of a monogenic disorder related to a gene in the EH family. The data demonstrate the pleiotropic effect of EPHX1 and its key role in cell homeostasis. This is consistent with the high evolutionary conservation of EHs across multiple organisms, including animals, insects, plants, fungi, and bacteria (van Loo et al., 2006), and underscores their essential biological function.

In this study, two different EPHX1 de novo missense variants were identified in patients with a progressive multisystemic disorder. According to the American College of Medical Genetics and Genomics (ACMG) criteria (Richards et al., 2015), these variants can be classified as ‘pathogenic’ with the inclusion of our functional data. The two patients share a number of clinical characteristics including dysmorphic features and manifestations affecting the liver, adipose tissue, and nervous system. The broad expression of EPHX1 explains how germline variants in this gene result in this multisystemic phenotype. As an example, EPHX1 transcripts have been detected in various areas of the brain (Farin and Omiecinski, 1993), and EPHX1 was also recently shown to play a complementary role to EPHX2 in the brain metabolism of naturally occurring EETs, which constitute a major class of EpFAs (Marowsky et al., 2016; Marowsky et al., 2009). The involvement of the EPHX1 de novo variants identified herein in diabetes and liver dysfunction is also consistent with a number of previous observations. Firstly, the expression of EPHX1 is regulated by various transcriptional factors including GATA4 and HNF4A (Liang et al., 2005; Peng et al., 2013), two genes implicated in other forms of monogenic diabetes. In regard to systemic hormonal regulation, it was demonstrated in primary hepatocytes that insulin positively and glucagon negatively regulate EPHX1 expression (Kim et al., 2003). A previous study also showed that a common polymorphism in EPHX1 (p.Tyr113His) was associated with an increased risk of type 2 diabetes mellitus and insulin resistance (Ghattas and Amer, 2012), as well as liver cirrhosis (Sonzogni et al., 2002). It was shown that EPHX1 plays a key role in the liver metabolism of endogenous lipids (Marowsky et al., 2017). Regarding hormonal pathophysiology, patient 1 developed amenorrhea associated with steroidogenesis alterations. Partial and generalized lipoatrophy are commonly associated with insulin resistance and hyperandrogenism (Joy and Hegele, 2008). Indeed, hyperinsulinemia directly stimulates ovarian androgen production, which in turn alters insulin sensitivity with a positive feedback loop between insulin resistance and hyperandrogenism. The major insulin resistance observed in patient 1 might thus contribute to hyperandrogenism signs. Nevertheless, her total testosterone levels are much higher than those usually observed in lipodystrophic patients (Huang-Doran et al., 2021). Such an elevation of testosterone levels in the absence of tumor and in the presence of normal estradiol levels rather argue for a direct or indirect blockade of the aromatase activity. In this regard, a potential role of EPHX1 in reproductive physiology was suggested previously. EPHX1 is expressed in ovarian follicle cells (Cannady et al., 2002) and is regulated by progesterone during the menstrual cycle (Popp et al., 2010). Several endogenous biologically active epoxide mediators of the steroidogenic pathway were found to be EPHX1 substrates, such as androstene oxide (16α,17α-epoxyandrosten-3-one) and estroxide (epoxyestratrienol) (Vogel-Bindel et al., 1982). EPHX1 protects cells from oxidative stress in oviducts (Cheong et al., 2009). A decrease in estradiol formation from testosterone was seen in human ovaries upon treatment with an EPHX1 inhibitor (Hattori et al., 2000). Polycystic ovary syndrome, characterized by hyperandrogenism and elevated serum testosterone levels, is observed in patients taking sodium valproate (Isojarvi et al., 1993), an anti-epileptic and anti-convulsant drug known to inhibit EPHX1 activity (Kerr et al., 1989). This observation is reminiscent of what is seen in our patient, who displays signs of hyperandrogenism in association with a loss of EPHX1 activity. The role of EPHX1 on the reproductive function could also be illustrated by the reported link between EPHX1 polymorphisms and spontaneous abortion (Wang et al., 1998) or preeclampsia (Laasanen et al., 2002). Consequently, further functional experiments in estrogen-producing granulosa cell models would be helpful to understand how EPHX1 could modulate aromatase activity or other steps of the steroidogenic pathway.

There were few data on the role of EPHX1 in adipose tissue, and its function in adipocytes remained elusive. The current study supports a role for EPHX1 in adipogenesis and adipocyte functions. We observed a defect in adipocyte differentiation in 3T3-L1 cells with CRISPR-Cas9 KO of Ephx1. This cellular model also revealed decreased expression of mature adipocyte markers, as well as altered insulin signaling even in pre-adipocytes. This is consistent with the lipoatrophic phenotype observed in the two patients carrying de novo EPHX1 pathogenic variants. Such an adipocyte differentiation defect has been reported in several other lipoatrophic diabetes of various genetic origins (Akinci et al., 2018a; Capel et al., 2018; Sollier et al., 2021). Lipoatrophic diabetes are indeed characterized by an incapacity of adipose tissue to store triglycerides, leading to ectopic fat depots and insulin resistance. The profound serum leptin and adiponectin deficiency observed in patients further confirms an endocrine defect of adipose tissue, since these hormones are secreted by mature adipocytes. What is the cellular link between the loss of EPHX1 activity and adipogenesis defect? EPHX1 substrates might play a key role since oxylipins, which are EPHX1 substrates, target peroxisome proliferator-activated receptors (PPARs) to modify adipocyte formation and function (Barquissau et al., 2017). It has also been reported that EETs decrease mesenchymal stem cells (MSC)-derived adipocyte differentiation by inhibiting PPARγ, C/EBPα, and FAS (Kim et al., 2010). In addition, PPARγ agonists have been shown to increase the expression of EPHX2 (De Taeye et al., 2010), whose expression is also interdependent of that of EPHX1 (Edin et al., 2018). Additional experiments will be required to precisely define the link between the loss of EPHX1 and adipogenesis alteration, which might involve the deregulation of PPARγ agonists or antagonists. Altogether, these data show that EPHX1, with its crucial role in epoxide reactive species biotransformation, stands at the crossroad of several signaling pathways and thereby plays a key role in cell metabolism and homeostasis.

EpFAs are endogenous lipid mediators functionally regulated in part by their hydrolysis by EPHX1 and EPHX2. Strategies stabilizing or mimicking EpFAs are commonly reported to contribute to cell homeostasis maintenance (Bettaieb et al., 2013; Wang et al., 2014; Liu et al., 2018). In this regard, it has been proposed that EpFAs prevent mitochondrial dysfunction, reduce ROS formation, and alleviate ER stress (Inceoglu et al., 2017). EETs exhibit numerous beneficial effects, such as anti-inflammatory, analgesic, vasodilatory, angiogenic, fibrinolytic, tissue-regenerating, and cytoprotective effects (Marowsky et al., 2017; Imig, 2012; Morisseau, 2013). This has been deeply investigated for EPHX2, and specific inhibitors have shown beneficial effects on a wide range of apparently unrelated conditions, including diabetes, fibrosis, chronic pain, cardiovascular, and neurodegenerative diseases (Ghosh et al., 2020), so that several of these EPHX2 inhibitors were tested in phase I clinical trials (Morisseau and Hammock, 2013; Imig and Hammock, 2009). In contrast, the current study shows that a loss of EPHX1 activity can be associated with a severe multisystemic phenotype. How to reconcile these apparently conflicting data? Like numerous other signaling molecules, the function of EpFAs strongly depend on the biological context (Inceoglu et al., 2017). The absence of a measurable effect of EpFAs under basal conditions is consistently observed across different laboratories and is in stark contrast to their strong efficacy under pathological situations. EpFAs seem to function with fine tuning to regulate and maintain cell homeostasis. This point is best illustrated by the ability of EPHX2 inhibitors to shift both hypertension and hypotension toward normotension in rodent models (Sinal et al., 2000; Ulu et al., 2016).

The gnomAD database, which collects variants from the general population, reports several dozen predicted loss-of-function variants in EPHX1, including nonsense, frameshift, and canonical splice site variants. This suggests that the pathogenic effect of the missense variants identified in patients 1 and 2 is not only due to a loss-of-function, but may be associated with a dominant negative mechanism. A previous study on the 3D-structure of EPHX1 suggests that this enzyme, which is mostly membrane bound, might be dimeric (Zou et al., 2000). This would be in favor of a dominant negative effect, as well as the formation of higher-order complexes within the ER observed in overexpression studies. Although this aspect of EPHX1 structure has so far been poorly explored, it may have important consequences for EPHX1 function, for example, by pre-orienting the enzyme for binding of either substrates or functional partners. We did not detect any dominant negative effect in the c-SO hydrolysis assay when co-expressing WT and mutated forms of EPHX1 (Figure 2—figure supplement 2). However, overexpression studies are probably not the most appropriate system to investigate such properties. Additional studies will be required to better understand EPHX1 activity when embedded in the microsomal ER membranes in endogenous conditions. In any case, the final result is a loss of the enzyme activity, consistent with the localization of the variants at the center of EPHX1 catalytic site. EPHX1 KO in 3T3-L1-pre-adipocytes revealed a high rate of ROS production, an observation confirmed in patient 1-derived fibroblasts. These data reinforce the proposed role of EHs as regulators of oxidative stress (Cheong et al., 2009; Inceoglu et al., 2017; Ulu et al., 2016). Patient 1-derived fibroblasts displayed an altered morphology, senescent features such as an increase in the SA-β-gal marker, as well as a reduced proliferative rate. This senescent phenotype was reproduced by removing EPHX1 in 3T3-L1 pre-adipocytes and ASCs, which subsequently loss their capacity to differentiate into adipocytes. Our findings not only support the notion that cellular senescence is an important player in adipogenesis, but also argue that EPHX1 might directly regulate adipocyte differentiation.

Regarding available animal models, Ephx1 knockout mice have already been generated (Miyata et al., 1999). Deletion of the gene in the heterozygous or homozygous state did not induce an obvious phenotype and histological examination of several organs revealed no difference between Ephx1-null mice and wild-type littermates. The first complexity when attempting to model lipodystrophy in mice is the differences between human and murine fat distribution and lipid metabolism, particularly the handling and oxidation of lipids (Rochford, 2014). So far, it appears that observations made in models of congenital generalized lipodystrophies (CGL) can translate quite accurately from mice to humans. Indeed, the most frequent CGL are autosomal recessive disorders due to bi-allelic null variants. In contrast, familial partial lipodystrophy syndromes are more difficult to study in mice, since they are often autosomal dominant and some variants induce a dominant negative effect (Garg, 2011). Knock-in mice would be required to better investigate such pathophysiological mechanisms for EPHX1 variants, and additional metabolic stress is sometimes needed to uncover more aspects of the human phenotype (Gray et al., 2006).

In this study, we were also interested in improving the therapeutic management of this novel clinical entity, which justifies careful clinical evaluation and requires multidisciplinary care. Patient 1 suffered from very severe diabetes with persistent glycemic imbalance despite very high insulin doses. Metreleptin was shown to reduce hyperphagia leading to weight loss, to improve insulin sensitivity and secretion, to reduce hypertriglyceridemia, hyperglycemia, and fatty liver disease in many patients with lipoatrophic diabetes (Vatier et al., 2016; Akinci et al., 2018b). All these beneficial effects were rapidly observed in patient 1 after treatment initiation. Besides, regarding the specific role of EPHX1 as a xenobiotic detoxifying enzyme, another practical implication of this study for the patient is the contraindication to all drugs known to be metabolized by EPHX1, especially carbamazepine, phenobarbital, and phenytoin (El-Sherbeni and El-Kadi, 2014). They would not be properly metabolized by EPHX1 and eliminated by the patient leading to toxicity.

The data presented here emphasize that lipid mediator regulation by EHs is essential for homeostasis and that its alteration is a newly discovered mechanism in monogenic insulin-resistant lipoatrophic diabetes. The field of monogenic diabetes is quickly advancing, and knowledge gained in recent years led to great improvements in understanding of their molecular and cellular bases. This allows to improve overall quality of life for patients and their families, with earlier diagnoses and personalized treatments. Continued efforts at gene discovery may help reveal mechanistic pathways implicated in the more common forms of type 1 and type 2 diabetes and lead to better treatments and outcomes.

Plasmids used in this study have been deposited in Addgene under accession number 79368. Exome data from human subjects cannot been made available, since the informed written consents did not permit sharing of the full sequence data. To circumvent this fact and to fit with the Editor and Reviewers' comment, two supplementary files have been provided listing all other rare variants identified in the two families investigated herein, according to the corresponding mode of inheritance. For each variant, we indicated the items arguing against its involvement in the disease phenotype. All data generated or analysed during this study are included in the manuscript and supporting files. Source data have been provided for all western blot experiments.

1. 1. Akinci B
   2. Meral R
   3. Oral EA

   (2018a) Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities

   Current Diabetes Reports 18:143.

   https://doi.org/10.1007/s11892-018-1099-9

   • PubMed
   • Google Scholar
2. 1. Akinci B
   2. Meral R
   3. Oral EA

   (2018b) Update on therapeutic options in lipodystrophy

   Current Diabetes Reports 18:139.

   https://doi.org/10.1007/s11892-018-1100-7

   • PubMed
   • Google Scholar
3. 1. Arand M
   2. Muller F
   3. Mecky A
   4. Hinz W
   5. Urban P
   6. Pompon D
   7. Kellner R
   8. Oesch F

   (1999) Catalytic triad of microsomal epoxide hydrolase: replacement of Glu404 with asp leads to a strongly increased turnover rate

   Biochemical Journal 337:37–43.

   https://doi.org/10.1042/bj3370037

   • Google Scholar
4. 1. Barquissau V
   2. Ghandour RA
   3. Ailhaud G
   4. Klingenspor M
   5. Langin D
   6. Amri EZ
   7. Pisani DF

   (2017) Control of adipogenesis by oxylipins, GPCRs and PPARs

   Biochimie 136:3–11.

   https://doi.org/10.1016/j.biochi.2016.12.012

   • PubMed
   • Google Scholar
5. 1. Bell PA
   2. Kasper CB

   (1993) Expression of rat microsomal epoxide hydrolase in Escherichia coli identification of a histidyl residue essential for catalysis

   Journal of Biological Chemistry 268:14011–14017.

   https://doi.org/10.1016/S0021-9258(19)85202-X

   • Google Scholar
6. 1. Bettaieb A
   2. Nagata N
   3. AbouBechara D
   4. Chahed S
   5. Morisseau C
   6. Hammock BD
   7. Haj FG

   (2013) Soluble epoxide hydrolase deficiency or inhibition attenuates Diet-induced endoplasmic reticulum stress in liver and adipose tissue

   Journal of Biological Chemistry 288:14189–14199.

   https://doi.org/10.1074/jbc.M113.458414

   • Google Scholar
7. 1. Bidault G
   2. Garcia M
   3. Vantyghem M-C
   4. Ducluzeau P-H
   5. Morichon R
   6. Thiyagarajah K
   7. Moritz S
   8. Capeau J
   9. Vigouroux C
   10. Béréziat V

   (2013) Lipodystrophy-Linked LMNA p.R482W Mutation Induces Clinical Early Atherosclerosis and In Vitro Endothelial Dysfunction

   Arteriosclerosis, Thrombosis, and Vascular Biology 33:2162–2171.

   https://doi.org/10.1161/ATVBAHA.113.301933

   • Google Scholar
8. 1. Blum M
   2. Dogan I
   3. Karber M
   4. Rothe M
   5. Schunck WH

   (2019) Chiral lipidomics of monoepoxy and monohydroxy metabolites derived from long-chain polyunsaturated fatty acids

   Journal of Lipid Research 60:135–148.

   https://doi.org/10.1194/jlr.M089755

   • PubMed
   • Google Scholar
9. 1. Brown RJ
   2. Araujo-Vilar D
   3. Cheung PT
   4. Dunger D
   5. Garg A
   6. Jack M
   7. Mungai L
   8. Oral EA
   9. Patni N
   10. Rother KI
   11. von Schnurbein J
   12. Sorkina E
   13. Stanley T
   14. Vigouroux C
   15. Wabitsch M
   16. Williams R
   17. Yorifuji T

   (2016) The diagnosis and management of lipodystrophy syndromes: a Multi-Society practice guideline

   The Journal of Clinical Endocrinology & Metabolism 101:4500–4511.

   https://doi.org/10.1210/jc.2016-2466

   • PubMed
   • Google Scholar
10. 1. Cannady EA
    2. Dyer CA
    3. Christian PJ
    4. Sipes IG
    5. Hoyer PB

    (2002) Expression and activity of microsomal epoxide hydrolase in follicles isolated from mouse ovaries

    Toxicological Sciences 68:24–31.

    https://doi.org/10.1093/toxsci/68.1.24

    • PubMed
    • Google Scholar
11. 1. Capel E
    2. Vatier C
    3. Cervera P
    4. Stojkovic T
    5. Disse E
    6. Cottereau AS
    7. Auclair M
    8. Verpont MC
    9. Mosbah H
    10. Gourdy P
    11. Barraud S
    12. Miquel A
    13. Züchner S
    14. Bonnefond A
    15. Froguel P
    16. Christin-Maitre S
    17. Delemer B
    18. Fève B
    19. Laville M
    20. Robert J
    21. Tenenbaum F
    22. Lascols O
    23. Vigouroux C
    24. Jéru I

    (2018) MFN2-associated lipomatosis: clinical spectrum and impact on adipose tissue

    Journal of Clinical Lipidology 12:1420–1435.

    https://doi.org/10.1016/j.jacl.2018.07.009

    • PubMed
    • Google Scholar
12. 1. Cheong AW
    2. Lee YL
    3. Liu WM
    4. Yeung WS
    5. Lee KF

    (2009) Oviductal microsomal epoxide hydrolase (EPHX1) reduces reactive oxygen species (ROS) level and enhances preimplantation mouse embryo development

    Biology of Reproduction 81:126–132.

    https://doi.org/10.1095/biolreprod.108.071449

    • PubMed
    • Google Scholar
13. 1. Coller JK
    2. Fritz P
    3. Zanger UM
    4. Siegle I
    5. Eichelbaum M
    6. Kroemer HK
    7. Mürdter TE

    (2001) Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours

    The Histochemical Journal 33:329–336.

    https://doi.org/10.1023/A:1012414806166

    • Google Scholar
14. 1. Davalli P
    2. Mitic T
    3. Caporali A
    4. Lauriola A
    5. D'Arca D

    (2016) ROS, cell senescence, and novel molecular mechanisms in aging and Age-Related diseases

    Oxidative Medicine and Cellular Longevity 2016:1–18.

    https://doi.org/10.1155/2016/3565127

    • PubMed
    • Google Scholar
15. 1. De Taeye BM
    2. Morisseau C
    3. Coyle J
    4. Covington JW
    5. Luria A
    6. Yang J
    7. Murphy SB
    8. Friedman DB
    9. Hammock BB
    10. Vaughan DE

    (2010) Expression and regulation of soluble epoxide hydrolase in adipose tissue

    Obesity 18:489–498.

    https://doi.org/10.1038/oby.2009.227

    • PubMed
    • Google Scholar
16. 1. Decker M
    2. Arand M
    3. Cronin A

    (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling

    Archives of Toxicology 83:297–318.

    https://doi.org/10.1007/s00204-009-0416-0

    • PubMed
    • Google Scholar
17. 1. Decker M
    2. Adamska M
    3. Cronin A
    4. Di Giallonardo F
    5. Burgener J
    6. Marowsky A
    7. Falck JR
    8. Morisseau C
    9. Hammock BD
    10. Gruzdev A
    11. Zeldin DC
    12. Arand M

    (2012) EH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides

    Journal of Lipid Research 53:2038–2045.

    https://doi.org/10.1194/jlr.M024448

    • PubMed
    • Google Scholar
18. 1. Edin ML
    2. Hamedani BG
    3. Gruzdev A
    4. Graves JP
    5. Lih FB
    6. Arbes SJ
    7. Singh R
    8. Orjuela Leon AC
    9. Bradbury JA
    10. DeGraff LM
    11. Hoopes SL
    12. Arand M
    13. Zeldin DC

    (2018) Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia

    Journal of Biological Chemistry 293:3281–3292.

    https://doi.org/10.1074/jbc.RA117.000298

    • Google Scholar
19. 1. El-Sherbeni AA
    2. El-Kadi AO

    (2014) The role of epoxide hydrolases in health and disease

    Archives of Toxicology 88:2013–2032.

    https://doi.org/10.1007/s00204-014-1371-y

    • PubMed
    • Google Scholar
20. 1. Farin FM
    2. Omiecinski CJ

    (1993) Regiospecific expression of cytochrome P‐450s and microsomal epoxide hydrolase in human brain tissue

    Journal of Toxicology and Environmental Health 40:317–335.

    https://doi.org/10.1080/15287399309531797

    • Google Scholar
21. 1. Fiorillo C
    2. D'Apice MR
    3. Trucco F
    4. Murdocca M
    5. Spitalieri P
    6. Assereto S
    7. Baratto S
    8. Morcaldi G
    9. Minetti C
    10. Sangiuolo F
    11. Novelli G

    (2018) Characterization of MDPL Fibroblasts Carrying the Recurrent p.Ser605del Mutation in POLD1 Gene

    DNA and Cell Biology 37:1061–1067.

    https://doi.org/10.1089/dna.2018.4335

    • Google Scholar
22. 1. Fretland AJ
    2. Omiecinski CJ

    (2000) Epoxide hydrolases: biochemistry and molecular biology

    Chemico-Biological Interactions 129:41–59.

    https://doi.org/10.1016/S0009-2797(00)00197-6

    • Google Scholar
23. 1. Friedberg T
    2. Löllmann B
    3. Becker R
    4. Holler R
    5. Oesch F

    (1994) The microsomal epoxide hydrolase has a single membrane signal anchor sequence which is dispensable for the catalytic activity of this protein

    Biochemical Journal 303:967–972.

    https://doi.org/10.1042/bj3030967

    • Google Scholar
24. 1. Garg A

    (2011) Clinical review#: Lipodystrophies: genetic and acquired body fat disorders

    The Journal of Clinical Endocrinology & Metabolism 96:3313–3325.

    https://doi.org/10.1210/jc.2011-1159

    • PubMed
    • Google Scholar
25. 1. Gautheron J
    2. Jéru I

    (2020) The multifaceted role of epoxide hydrolases in human health and disease

    International Journal of Molecular Sciences 22:13.

    https://doi.org/10.3390/ijms22010013

    • Google Scholar
26. 1. Ghattas MH
    2. Amer MA

    (2012) Possible role of microsomal epoxide hydrolase gene polymorphism as a risk factor for developing insulin resistance and type 2 diabetes mellitus

    Endocrine 42:577–583.

    https://doi.org/10.1007/s12020-012-9656-5

    • Google Scholar
27. 1. Ghosh A
    2. Comerota MM
    3. Wan D
    4. Chen F
    5. Propson NE
    6. Hwang SH
    7. Hammock BD
    8. Zheng H

    (2020) An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of alzheimer's disease

    Science Translational Medicine 12:eabb1206.

    https://doi.org/10.1126/scitranslmed.abb1206

    • PubMed
    • Google Scholar
28. 1. Gray SL
    2. Nora ED
    3. Grosse J
    4. Manieri M
    5. Stoeger T
    6. Medina-Gomez G
    7. Burling K
    8. Wattler S
    9. Russ A
    10. Yeo GS
    11. Chatterjee VK
    12. O'Rahilly S
    13. Voshol PJ
    14. Cinti S
    15. Vidal-Puig A

    (2006) Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice

    Diabetes 55:2669–2677.

    https://doi.org/10.2337/db06-0389

    • PubMed
    • Google Scholar
29. 1. Haque WA
    2. Shimomura I
    3. Matsuzawa Y
    4. Garg A

    (2002) Serum adiponectin and leptin levels in patients with lipodystrophies

    The Journal of Clinical Endocrinology & Metabolism 87:2395.

    https://doi.org/10.1210/jcem.87.5.8624

    • PubMed
    • Google Scholar
30. 1. Hassett C
    2. Aicher L
    3. Sidhu JS
    4. Omiecinski CJ

    (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants

    Human Molecular Genetics 3:421–428.

    https://doi.org/10.1093/hmg/3.3.421

    • PubMed
    • Google Scholar
31. 1. Hattori N
    2. Fujiwara H
    3. Maeda M
    4. Fujii S
    5. Ueda M

    (2000) Epoxide hydrolase affects estrogen production in the human ovary

    Endocrinology 141:3353–3365.

    https://doi.org/10.1210/endo.141.9.7682

    • PubMed
    • Google Scholar
32. 1. Huang-Doran I
    2. Kinzer AB
    3. Jimenez-Linan M
    4. Thackray K
    5. Harris J
    6. Adams CL
    7. de Kerdanet M
    8. Stears A
    9. O'Rahilly S
    10. Savage DB
    11. Gorden P
    12. Brown RJ
    13. Semple RK

    (2021) Ovarian hyperandrogenism and response to Gonadotropin-releasing hormone analogues in primary severe insulin resistance

    The Journal of Clinical Endocrinology & Metabolism 106:2367–2383.

    https://doi.org/10.1210/clinem/dgab275

    • PubMed
    • Google Scholar
33. 1. Imboden MT
    2. Welch WA
    3. Swartz AM
    4. Montoye AHK
    5. Finch HW
    6. Harber MP
    7. Kaminsky LA

    (2017) Reference standards for body fat measures using GE dual energy x-ray absorptiometry in caucasian adults

    PLOS ONE 12:e0175110.

    https://doi.org/10.1371/journal.pone.0175110

    • PubMed
    • Google Scholar
34. 1. Imig JD

    (2012) Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology

    Physiological Reviews 92:101–130.

    https://doi.org/10.1152/physrev.00021.2011

    • Google Scholar
35. 1. Imig JD
    2. Hammock BD

    (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

    Nature Reviews Drug Discovery 8:794–805.

    https://doi.org/10.1038/nrd2875

    • Google Scholar
36. 1. Inceoglu B
    2. Bettaieb A
    3. Haj FG
    4. Gomes AV
    5. Hammock BD

    (2017) Modulation of mitochondrial dysfunction and endoplasmic reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids and soluble epoxide hydrolase inhibitors

    Prostaglandins & Other Lipid Mediators 133:68–78.

    https://doi.org/10.1016/j.prostaglandins.2017.08.003

    • Google Scholar
37. 1. Isojarvi J
    2. Laatikainen TJ
    3. Pakarinen AJ
    4. Juntunen K
    5. Myllyla VV

    (1993) Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy

    New England Journal of Medicine 329:1383–1388.

    https://doi.org/10.1056/NEJM199311043291904

    • Google Scholar
38. 1. Jéru I
    2. Vantyghem M-C
    3. Bismuth E
    4. Cervera P
    5. Barraud S
    6. Auclair M
    7. Vatier C
    8. Lascols O
    9. Savage DB
    10. Vigouroux C
    11. Group PL-S

    (2019) Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy

    The Journal of Clinical Endocrinology & Metabolism 104:6025–6032.

    https://doi.org/10.1210/jc.2019-00849

    • Google Scholar
39. 1. Joy TR
    2. Hegele RA

    (2008) Prevalence of Reproductive Abnormalities Among Women with Familial Partial Lipodystrophy

    Endocrine Practice 14:1126–1132.

    https://doi.org/10.4158/EP.14.9.1126

    • Google Scholar
40. 1. Kelly TL
    2. Wilson KE
    3. Heymsfield SB

    (2009) Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANES

    PLOS ONE 4:e7038.

    https://doi.org/10.1371/journal.pone.0007038

    • Google Scholar
41. 1. Kerr BM
    2. Rettie AE
    3. Eddy AC
    4. Loiseau P
    5. Guyot M
    6. Wilensky AJ
    7. Levy RH

    (1989) Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation

    Clinical Pharmacology and Therapeutics 46:82–93.

    https://doi.org/10.1038/clpt.1989.110

    • Google Scholar
42. 1. Kim SK
    2. Woodcroft KJ
    3. Kim SG
    4. Novak RF

    (2003) Insulin and glucagon signaling in regulation of microsomal epoxide hydrolase expression in primary cultured rat hepatocytes

    Drug Metabolism and Disposition 31:1260–1268.

    https://doi.org/10.1124/dmd.31.10.1260

    • Google Scholar
43. 1. Kim DH
    2. Vanella L
    3. Inoue K
    4. Burgess A
    5. Gotlinger K
    6. Manthati VL
    7. Koduru SR
    8. Zeldin DC
    9. Falck JR
    10. Schwartzman ML
    11. Abraham NG

    (2010) Epoxyeicosatrienoic Acid Agonist Regulates Human Mesenchymal Stem Cell–Derived Adipocytes Through Activation of HO-1-pAKT Signaling and a Decrease in PPARγ

    Stem Cells and Development 19:1863–1873.

    https://doi.org/10.1089/scd.2010.0098

    • Google Scholar
44. 1. Laasanen J
    2. Romppanen E-L
    3. Hiltunen M
    4. Helisalmi S
    5. Mannermaa A
    6. Punnonen K
    7. Heinonen S

    (2002) Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia

    European Journal of Human Genetics 10:569–573.

    https://doi.org/10.1038/sj.ejhg.5200849

    • Google Scholar
45. 1. Letourneau LR
    2. Greeley SAW

    (2018) Congenital forms of diabetes: the beta-cell and beyond

    Current Opinion in Genetics & Development 50:25–34.

    https://doi.org/10.1016/j.gde.2018.01.005

    • Google Scholar
46. 1. Lewis DFV
    2. Lake BG
    3. Bird MG

    (2005) Molecular modelling of human microsomal epoxide hydrolase (EH) by homology with a fungal (Aspergillus niger) EH crystal structure of 1.8 Å resolution: structure–activity relationships in epoxides inhibiting EH activity

    Toxicology in Vitro 19:517–522.

    https://doi.org/10.1016/j.tiv.2004.07.001

    • Google Scholar
47. 1. Liang S-H
    2. Hassett C
    3. Omiecinski CJ

    (2005) Alternative promoters determine tissue-specific expression profiles of the human microsomal epoxide hydrolase gene (EPHX1)

    Molecular Pharmacology 67:220–230.

    https://doi.org/10.1124/mol.104.005579

    • Google Scholar
48. 1. Liu L
    2. Puri N
    3. Raffaele M
    4. Schragenheim J
    5. Singh SP
    6. Bradbury JA
    7. Bellner L
    8. Vanella L
    9. Zeldin DC
    10. Cao J
    11. Abraham NG

    (2018) Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo

    Prostaglandins & Other Lipid Mediators 138:1–8.

    https://doi.org/10.1016/j.prostaglandins.2018.07.004

    • Google Scholar
49. 1. López-Otín C
    2. Blasco MA
    3. Partridge L
    4. Serrano M
    5. Kroemer G

    (2013) The Hallmarks of Aging

    Cell 153:1194–1217.

    https://doi.org/10.1016/j.cell.2013.05.039

    • Google Scholar
50. 1. Marowsky A
    2. Burgener J
    3. Falck JR
    4. Fritschy J-M
    5. Arand M

    (2009) Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism

    Neuroscience 163:646–661.

    https://doi.org/10.1016/j.neuroscience.2009.06.033

    • Google Scholar
51. 1. Marowsky A
    2. Haenel K
    3. Bockamp E
    4. Heck R
    5. Rutishauser S
    6. Mule N
    7. Kindler D
    8. Rudin M
    9. Arand M

    (2016) Genetic enhancement of microsomal epoxide hydrolase improves metabolic detoxification but impairs cerebral blood flow regulation

    Archives of Toxicology 90:3017–3027.

    https://doi.org/10.1007/s00204-016-1666-2

    • Google Scholar
52. 1. Marowsky A
    2. Meyer I
    3. Erismann-Ebner K
    4. Pellegrini G
    5. Mule N
    6. Arand M

    (2017) Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids

    Archives of Toxicology 91:3571–3585.

    https://doi.org/10.1007/s00204-017-2060-4

    • Google Scholar
53. 1. McReynolds C
    2. Morisseau C
    3. Wagner K
    4. Hammock B

    (2020) Epoxy fatty acids are promising targets for treatment of pain, cardiovascular disease and other indications characterized by mitochondrial dysfunction, endoplasmic stress and inflammation

    Advances in Experimental Medicine and Biology 1274:71–99.

    https://doi.org/10.1007/978-3-030-50621-6_5

    • PubMed
    • Google Scholar
54. 1. Miyata M
    2. Kudo G
    3. Lee YH
    4. Yang TJ
    5. Gelboin HV
    6. Fernandez-Salguero P
    7. Kimura S
    8. Gonzalez FJ

    (1999) Targeted disruption of the microsomal epoxide hydrolase gene microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene

    The Journal of Biological Chemistry 274:23963–23968.

    https://doi.org/10.1074/jbc.274.34.23963

    • PubMed
    • Google Scholar
55. 1. Morisseau C

    (2013) Role of epoxide hydrolases in lipid metabolism

    Biochimie 95:91–95.

    https://doi.org/10.1016/j.biochi.2012.06.011

    • PubMed
    • Google Scholar
56. 1. Morisseau C
    2. Kodani SD
    3. Kamita SG
    4. Yang J
    5. Lee KSS
    6. Hammock BD

    (2021) Relative importance of soluble and microsomal epoxide hydrolases for the hydrolysis of Epoxy-Fatty acids in human tissues

    International Journal of Molecular Sciences 22:4993.

    https://doi.org/10.3390/ijms22094993

    • PubMed
    • Google Scholar
57. 1. Morisseau C
    2. Hammock BD

    (2007) Measurement of soluble epoxide hydrolase (sEH) activity

    Current Protocols in Toxicology 4:23.

    https://doi.org/10.1002/0471140856.tx0423s33

    • PubMed
    • Google Scholar
58. 1. Morisseau C
    2. Hammock BD

    (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health

    Annual Review of Pharmacology and Toxicology 53:37–58.

    https://doi.org/10.1146/annurev-pharmtox-011112-140244

    • PubMed
    • Google Scholar
59. 1. Munteanu M
    2. Ratziu V
    3. Morra R
    4. Messous D
    5. Imbert-Bismut F
    6. Poynard T

    (2008)

    Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: fibrotest-fibromax experience

    Journal of Gastrointestinal and Liver Diseases : JGLD 17:187–191.

    • PubMed
    • Google Scholar
60. 1. Nebert DW
    2. Dalton TP

    (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis

    Nature Reviews Cancer 6:947–960.

    https://doi.org/10.1038/nrc2015

    • Google Scholar
61. 1. Nithipatikom K
    2. Endsley MP
    3. Pfeiffer AW
    4. Falck JR
    5. Campbell WB

    (2014) A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol

    Journal of Lipid Research 55:2093–2102.

    https://doi.org/10.1194/jlr.M051284

    • Google Scholar
62. 1. Oesch F
    2. Jerina DM
    3. Daly JW

    (1971) Substrate specificity of hepatic epoxide hydrase in microsomes and in a purified preparation: Evidence for homologous enzymes

    Archives of Biochemistry and Biophysics 144:253–261.

    https://doi.org/10.1016/0003-9861(71)90476-0

    • Google Scholar
63. 1. Oesch F
    2. Jerina DM
    3. Daly JW
    4. Rice JM
    5. Induction RJM

    (1973) Induction, activation and inhibition of epoxide hydrase: an anomalous prevention of chlorobenzene-induced hepatotoxicity by an inhibitor of epoxide hydrase

    Chemico-Biological Interactions 6:189–202.

    https://doi.org/10.1016/0009-2797(73)90071-9

    • Google Scholar
64. 1. Oesch F
    2. Herrero ME
    3. Hengstler JG
    4. Lohmann M
    5. Arand M

    (2000) Metabolic Detoxification: Implications for Thresholds

    Toxicologic Pathology 28:382–387.

    https://doi.org/10.1177/019262330002800305

    • Google Scholar
65. 1. Peng H
    2. Zhu QS
    3. Zhong S
    4. Levy D

    (2013) Transcription of the human microsomal epoxide hydrolase gene (EPHX1) is regulated by an HNF-4α/CAR/RXR/PSF complex

    Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1829:1000–1009.

    https://doi.org/10.1016/j.bbagrm.2013.05.003

    • PubMed
    • Google Scholar
66. 1. Popp SL
    2. Abele IS
    3. Buck MB
    4. Stope MB
    5. Blok LJ
    6. Hanifi-Moghaddam P
    7. Burger CW
    8. Fritz P
    9. Knabbe C

    (2010) Microsomal epoxide hydrolase expression in the endometrial uterine corpus is regulated by progesterone during the menstrual cycle

    Journal of Molecular Histology 41:111–119.

    https://doi.org/10.1007/s10735-010-9266-6

    • Google Scholar
67. 1. Qian Y
    2. Chen X

    (2013) Senescence regulation by the p53 protein family

    Methods in Molecular Biology 965:37–61.

    https://doi.org/10.1007/978-1-62703-239-1_3

    • PubMed
    • Google Scholar
68. 1. Retterer K
    2. Juusola J
    3. Cho MT
    4. Vitazka P
    5. Millan F
    6. Gibellini F
    7. Vertino-Bell A
    8. Smaoui N
    9. Neidich J
    10. Monaghan KG
    11. McKnight D
    12. Bai R
    13. Suchy S
    14. Friedman B
    15. Tahiliani J
    16. Pineda-Alvarez D
    17. Richard G
    18. Brandt T
    19. Haverfield E
    20. Chung WK
    21. Bale S

    (2016) Clinical application of whole-exome sequencing across clinical indications

    Genetics in Medicine 18:696–704.

    https://doi.org/10.1038/gim.2015.148

    • Google Scholar
69. 1. Richards S
    2. Aziz N
    3. Bale S
    4. Bick D
    5. Das S
    6. Gastier-Foster J
    7. Grody WW
    8. Hegde M
    9. Lyon E
    10. Spector E
    11. Voelkerding K
    12. Rehm HL

    (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

    Genetics in Medicine 17:405–423.

    https://doi.org/10.1038/gim.2015.30

    • Google Scholar
70. 1. Rochford JJ

    (2014) Mouse models of lipodystrophy and their significance in understanding fat regulation

    Current Topics in Developmental Biology 109:53–96.

    https://doi.org/10.1016/B978-0-12-397920-9.00005-6

    • PubMed
    • Google Scholar
71. 1. Sinal CJ
    2. Miyata M
    3. Tohkin M
    4. Nagata K
    5. Bend JR
    6. Gonzalez FJ

    (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation

    Journal of Biological Chemistry 275:40504–40510.

    https://doi.org/10.1074/jbc.M008106200

    • Google Scholar
72. 1. Snider NT
    2. Kornilov AM
    3. Kent UM
    4. Hollenberg PF

    (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides

    Journal of Pharmacology and Experimental Therapeutics 321:590–597.

    https://doi.org/10.1124/jpet.107.119321

    • Google Scholar
73. 1. Sobreira N
    2. Schiettecatte F
    3. Valle D
    4. Hamosh A

    (2015) Genematcher: a matching tool for connecting investigators with an interest in the same gene

    Human Mutation 36:928–930.

    https://doi.org/10.1002/humu.22844

    • Google Scholar
74. 1. Sollier C
    2. Vatier C
    3. Capel E
    4. Lascols O
    5. Auclair M
    6. Janmaat S
    7. Fève B
    8. Jéru I
    9. Vigouroux C

    (2020) Lipodystrophic syndromes: From diagnosis to treatment

    Annales d'Endocrinologie 81:51–60.

    https://doi.org/10.1016/j.ando.2019.10.003

    • Google Scholar
75. 1. Sollier C
    2. Capel E
    3. Aguilhon C
    4. Smirnov V
    5. Auclair M
    6. Douillard C
    7. Ladsous M
    8. Defoort-Dhellemmes S
    9. Gorwood J
    10. Braud L
    11. Motterlini R
    12. Vatier C
    13. Lascols O
    14. Renard E
    15. Vigouroux C
    16. Jéru I

    (2021) LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells

    European Journal of Endocrinology 184:155–168.

    https://doi.org/10.1530/EJE-20-1013

    • Google Scholar
76. 1. Sonzogni L
    2. Silvestri L
    3. De Silvestri A
    4. Gritti C
    5. Foti L
    6. Zavaglia C
    7. Bottelli R
    8. Mondelli MU
    9. Civardi E
    10. Silini EM

    (2002) Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease

    Hepatology 36:195–201.

    https://doi.org/10.1053/jhep.2002.33898

    • Google Scholar
77. 1. Tchkonia T
    2. Morbeck DE
    3. Von Zglinicki T
    4. Van Deursen J
    5. Lustgarten J
    6. Scrable H
    7. Khosla S
    8. Jensen MD
    9. Kirkland JL

    (2010) Fat tissue, aging, and cellular senescence

    Aging Cell 9:667–684.

    https://doi.org/10.1111/j.1474-9726.2010.00608.x

    • Google Scholar
78. 1. Ulu A
    2. Inceoglu B
    3. Yang J
    4. Singh V
    5. Vito S
    6. Wulff H
    7. Hammock BD

    (2016) Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension

    Journal of Clinical Toxicology 6:1000300.

    https://doi.org/10.4172/2161-0495.1000300

    • PubMed
    • Google Scholar
79. 1. Václavíková R
    2. Hughes DJ
    3. Souček P

    (2015) Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease

    Gene 571:1–8.

    https://doi.org/10.1016/j.gene.2015.07.071

    • PubMed
    • Google Scholar
80. 1. van Loo B
    2. Kingma J
    3. Arand M
    4. Wubbolts MG
    5. Janssen DB

    (2006) Diversity and biocatalytic potential of epoxide hydrolases identified by genome analysis

    Applied and Environmental Microbiology 72:2905–2917.

    https://doi.org/10.1128/AEM.72.4.2905-2917.2006

    • Google Scholar
81. 1. Vatier C
    2. Fetita S
    3. Boudou P
    4. Tchankou C
    5. Deville L
    6. Riveline JP
    7. Young J
    8. Mathivon L
    9. Travert F
    10. Morin D
    11. Cahen J
    12. Lascols O
    13. Andreelli F
    14. Reznik Y
    15. Mongeois E
    16. Madelaine I
    17. Vantyghem MC
    18. Gautier JF
    19. Vigouroux C

    (2016) One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes

    Diabetes, Obesity and Metabolism 18:693–697.

    https://doi.org/10.1111/dom.12606

    • Google Scholar
82. 1. Vogel-Bindel U
    2. Bentley P
    3. Oesch F

    (1982)

    Endogenous role of microsomal epoxide hydrolase Ontogenesis, induction inhibition, tissue distribution, immunological behaviour and purification of microsomal epoxide hydrolase with 16 Alpha, 17 alpha-epoxyandrostene-3-one as substrate

    European Journal of Biochemistry 126:425–431.

    • PubMed
    • Google Scholar
83. 1. Wang X
    2. Wang M
    3. Niu T
    4. Chen C
    5. Xu X

    (1998) Microsomal epoxide hydrolase polymorphism and risk of spontaneous abortion

    Epidemiology 9:540–544.

    https://doi.org/10.1097/00001648-199809000-00012

    • Google Scholar
84. 1. Wang X
    2. Ni L
    3. Yang L
    4. Duan Q
    5. Chen C
    6. Edin ML
    7. Zeldin DC
    8. Wang DW

    (2014) CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure

    Molecular Pharmacology 85:105–115.

    https://doi.org/10.1124/mol.113.087122

    • Google Scholar
85. 1. Waterhouse A
    2. Bertoni M
    3. Bienert S
    4. Studer G
    5. Tauriello G
    6. Gumienny R
    7. Heer FT
    8. de Beer TAP
    9. Rempfer C
    10. Bordoli L
    11. Lepore R
    12. Schwede T

    (2018) SWISS-MODEL: homology modelling of protein structures and complexes

    Nucleic Acids Research 46:W296–W303.

    https://doi.org/10.1093/nar/gky427

    • Google Scholar
86. 1. Yang J
    2. Schmelzer K
    3. Georgi K
    4. Hammock BD

    (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry

    Analytical Chemistry 81:8085–8093.

    https://doi.org/10.1021/ac901282n

    • Google Scholar
87. 1. Zou J
    2. Hallberg BM
    3. Bergfors T
    4. Oesch F
    5. Arand M
    6. Mowbray SL
    7. Jones TA

    (2000) Structure of Aspergillus niger epoxide hydrolase at 1.8 Å resolution: implications for the structure and function of the mammalian microsomal class of epoxide hydrolases

    Structure 8:111–122.

    https://doi.org/10.1016/S0969-2126(00)00087-3

    • Google Scholar

Author details

1. Jeremie Gautheron

   1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
   2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-7727-9893

2. Christophe Morisseau

   Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States

   Contribution

   Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

3. Wendy K Chung

   1. Department of Pediatrics, Columbia University Irving Medical Center, New York, United States
   2. Deparment of Medicine, Columbia University Irving Medical Center, New York, United States

   Contribution

   Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

4. Jamila Zammouri

   1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
   2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

   Contribution

   Data curation, Formal analysis, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

5. Martine Auclair

   1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
   2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

   Contribution

   Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

6. Genevieve Baujat

   Service de Génétique Clinique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France

   Contribution

   Data curation, Formal analysis, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

7. Emilie Capel

   1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
   2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

   Contribution

   Data curation, Formal analysis, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

8. Celia Moulin

   1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
   2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

   Contribution

   Data curation, Formal analysis, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

9. Yuxin Wang

   Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States

   Contribution

   Data curation, Formal analysis, Investigation, Writing - review and editing

   Competing interests

   No competing interests declared

10. Jun Yang

    Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States

    Contribution

    Data curation, Formal analysis, Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

11. Bruce D Hammock

    Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, United States

    Contribution

    Data curation, Formal analysis, Writing - review and editing

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-1408-8317

12. Barbara Cerame

    Goryeb Children’s Hospital, Atlantic Health Systems, Morristown Memorial Hospital, Morristown, United States

    Contribution

    Data curation, Formal analysis, Writing - review and editing

    Competing interests

    No competing interests declared

13. Franck Phan

    1. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
    2. Service de Diabétologie-Métabolisme, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
    3. Sorbonne Université-Inserm UMRS_1269, Paris, France

    Contribution

    Data curation, Formal analysis, Writing - review and editing

    Competing interests

    No competing interests declared

14. Bruno Fève

    1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
    2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
    3. Centre National de Référence des Pathologies Rares de l’Insulino-Sécrétion et de l’Insulino-Sensibilité (PRISIS), Service de Diabétologie et Endocrinologie de la Reproduction, Hôpital Saint-Antoine, AP-HP, Paris, France

    Contribution

    Conceptualization, Formal analysis, Validation, Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

15. Corinne Vigouroux

    1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
    2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
    3. Centre National de Référence des Pathologies Rares de l’Insulino-Sécrétion et de l’Insulino-Sensibilité (PRISIS), Service de Diabétologie et Endocrinologie de la Reproduction, Hôpital Saint-Antoine, AP-HP, Paris, France
    4. Laboratoire commun de Biologie et Génétique Moléculaires, Hôpital Saint-Antoine, AP-HP, Paris, France

    Contribution

    Conceptualization, Formal analysis, Validation, Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

16. Fabrizio Andreelli

    1. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
    2. Service de Diabétologie-Métabolisme, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
    3. Sorbonne Université-Inserm UMRS_1269, Paris, France

    Contribution

    Conceptualization, Formal analysis, Validation, Investigation, Writing - review and editing

    Competing interests

    No competing interests declared

17. Isabelle Jeru

    1. Sorbonne Université-Inserm UMRS_938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
    2. Institute of Cardiometabolism and Nutrition (ICAN), CHU Pitié-Salpêtrière - Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
    3. Laboratoire commun de Biologie et Génétique Moléculaires, Hôpital Saint-Antoine, AP-HP, Paris, France

    Contribution

    Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing

    For correspondence

    isabelle.jeru@aphp.fr

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-7171-0577

• 1,305

  views

• 157

  downloads

• 20

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.